Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T39977
|
||||
| Former ID |
TTDC00103
|
||||
| Target Name |
Macrophage migration inhibitory factor
|
||||
| Gene Name |
MIF
|
||||
| Synonyms |
GIF; Glycosylation-inhibiting factor; Phenylpyruvate tautomerase; MIF
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
| Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
| Refractory autoimmune diseases [ICD9: 279.4; ICD10: D84.9, M35.9] | |||||
| Function |
Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti- inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is notclear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.
|
||||
| BioChemical Class |
Intramolecular oxidoreductases
|
||||
| Target Validation |
T39977
|
||||
| UniProt ID | |||||
| EC Number |
EC 5.3.3.12
|
||||
| Sequence |
MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALC
SLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Anti-MIF antibodies | Drug Info | Phase 4 | Autoimmune diabetes | [1] |
| ISO-1 | Drug Info | Phase 1 | Discovery agent | [2] | |
| COR100140 | Drug Info | Preclinical | Inflammatory disease | [3] | |
| Inhibitor | 3,4-Dihydroxycinnamic Acid | Drug Info | [4] | ||
| 3-(4-HYDROXY-PHENYL)PYRUVIC ACID | Drug Info | [5] | |||
| 4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME | Drug Info | [5] | |||
| 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE | Drug Info | [5] | |||
| Anti-MIF antibodies | Drug Info | [6] | |||
| AVP-13546 | Drug Info | [7] | |||
| AVP-13748 | Drug Info | [7] | |||
| COR100140 | Drug Info | [8] | |||
| ISO-1 | Drug Info | [9] | |||
| NAPQI | Drug Info | [7] | |||
| Pathways | |||||
| KEGG Pathway | Tyrosine metabolism | ||||
| Phenylalanine metabolism | |||||
| PathWhiz Pathway | Tyrosine Metabolism | ||||
| WikiPathways | Spinal Cord Injury | ||||
| Adipogenesis | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01452997) Evaluation of Anti-inflammatories in the Reduction of Bite Reactions. U.S. National Institutes of Health. | ||||
| REF 2 | ClinicalTrials.gov (NCT02284919) [18F]ISO-1 PET/CT in Breast Cancer. U.S. National Institutes of Health. | ||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020117) | ||||
| REF 4 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 5 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | ||||
| REF 6 | Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455. | ||||
| REF 7 | MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9. | ||||
| REF 8 | Cortical Pty Ltd Presents MIF Antagonist Data at World Congress on Inflammation. Cortical Pty Ltd. 2005. | ||||
| REF 9 | The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82. Epub 2002 May 7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.